Practice · Europe ⟶ China
Rare disease in China: approval is not access.
A structured approach for international pharmaceutical and biotech companies navigating China's regulatory, access and ecosystem complexity — where early missteps lock companies into suboptimal pathways for years.
The market
A national priority, still a hard market
China is home to an estimated 20 million patients affected by rare diseases. Over the past decade the field has become a national healthcare priority: the Rare Disease List has opened priority review pathways, and the spread of next-generation sequencing has changed what diagnosis is possible.
And yet reimbursement remains fragmented between national and provincial levels, and infrastructure varies sharply between major urban centres and lower-tier regions. Success requires regulatory, access, pricing and ecosystem strategies executed in the correct order.
Why entries fail
- Assuming Rare Disease List inclusion guarantees pricing or reimbursement.
- Misalignment between regulatory approval and diagnostic readiness.
- Underestimating the role of genetic-testing access in patient identification.
- Entering licensing or distribution agreements too early.
Our role
A China authority and an operating partner
We reduce strategic, regulatory and personal risk for the people who have to decide. We combine regulatory expertise, medical-scientific understanding and on-the-ground engagement — and we take responsibility for execution.
- Opportunity validation through real-world epidemiology and unmet-need assessment
- NMPA registration and access strategies aligned with clinical development stage
- Mapping and qualification of reference centres, hospitals and investigators
- Engagement with clinicians, KOLs and patient organisations
- Pricing, reimbursement and access scenarios under evolving NRDL frameworks
- Structured pilots supporting evidence-based scale-up — or a clean strategic exit
White paper
Strategic Entry into China's Rare Disease Market
A practical guide covering regulatory pathways, genetic-testing dynamics, pricing and reimbursement frameworks, digital health platforms and go-to-market strategy. Grounded in first-hand orphan-drug and NMPA experience — written for internal strategy and investment decisions, not as promotional content.
What you can engage us for here
A sector practice is not a separate service.
It is the evidence that we have run these services before in rare disease — the regulatory particularities, the buyers, the failure patterns and the published work. The engagement itself is one of these.
Market study & primary interviews
Patient-flow reality, treating-centre mapping and interviews with the clinicians who actually diagnose.
What it involves → Scoped engagementRegulatory pathway & access
Orphan designation, the catalogue route, and what approval does and does not buy you.
What it involves → Scoped engagementDistributor search & commercialisation
Importation route, named-patient channels and the partners who can service a small volume properly.
What it involves →